HK1033281A1 - Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates - Google Patents

Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates

Info

Publication number
HK1033281A1
HK1033281A1 HK01104097A HK01104097A HK1033281A1 HK 1033281 A1 HK1033281 A1 HK 1033281A1 HK 01104097 A HK01104097 A HK 01104097A HK 01104097 A HK01104097 A HK 01104097A HK 1033281 A1 HK1033281 A1 HK 1033281A1
Authority
HK
Hong Kong
Prior art keywords
hydrates
active ingredient
suitable salts
pharmaceutically suitable
medicinal preparations
Prior art date
Application number
HK01104097A
Other languages
English (en)
Inventor
Johannes Bartholomaus
Jurgen Betzing
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of HK1033281A1 publication Critical patent/HK1033281A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK01104097A 1998-05-09 2001-06-14 Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates HK1033281A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19820801A DE19820801A1 (de) 1998-05-09 1998-05-09 Orale Arzneiformen mit reproduzierbarer Wirkstofffreisetzung von Gatifloxacin oder pharmazeutisch verwendbaren Salzen oder Hydraten
PCT/EP1999/002893 WO1999058129A1 (de) 1998-05-09 1999-04-29 Orale arzneiformen mit reproduzierbarer wirkstofffreisetzung von gatifloxacin oder pharmazeutisch verwendbaren salzen oder hydraten

Publications (1)

Publication Number Publication Date
HK1033281A1 true HK1033281A1 (en) 2001-08-24

Family

ID=7867223

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01104097A HK1033281A1 (en) 1998-05-09 2001-06-14 Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates

Country Status (28)

Country Link
US (1) US6291462B1 (pt)
EP (1) EP1077703B1 (pt)
JP (1) JP2002514600A (pt)
KR (1) KR100587210B1 (pt)
CN (1) CN1198615C (pt)
AR (1) AR019279A1 (pt)
AT (1) ATE235242T1 (pt)
AU (1) AU753482B2 (pt)
BR (1) BR9910350A (pt)
CA (1) CA2325636A1 (pt)
CO (1) CO5050341A1 (pt)
DE (2) DE19820801A1 (pt)
DK (1) DK1077703T3 (pt)
ES (1) ES2195573T3 (pt)
HK (1) HK1033281A1 (pt)
HU (1) HUP0101597A3 (pt)
IL (1) IL139512A0 (pt)
MY (1) MY118569A (pt)
NO (1) NO20005385D0 (pt)
NZ (1) NZ507968A (pt)
PE (1) PE20000480A1 (pt)
PL (1) PL343936A1 (pt)
PT (1) PT1077703E (pt)
RU (1) RU2226394C2 (pt)
SK (1) SK16772000A3 (pt)
UA (1) UA60364C2 (pt)
WO (1) WO1999058129A1 (pt)
ZA (1) ZA200006440B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302015B6 (cs) 1999-10-08 2010-09-08 Affinium Pharmaceuticals, Inc. Inhibitory Fab I
US6413969B1 (en) * 2000-09-13 2002-07-02 Bristol-Myers Squibb Company Gatifloxacin pentahydrate
ATE420640T1 (de) * 2001-04-06 2009-01-15 Affinium Pharm Inc Fab-i-inhibitoren
US6589955B2 (en) * 2001-06-20 2003-07-08 Bristol-Myers Squibb Company Pediatric formulation of gatifloxacin
DK1575951T3 (da) * 2002-12-06 2014-09-15 Debiopharm Int Sa Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
EP1608377B1 (en) 2003-03-17 2008-10-01 Affinium Pharmaceuticals, Inc. Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
WO2005021000A1 (en) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Solid oral dosage forms of gatifloxacin
MY144477A (en) * 2004-03-17 2011-09-30 Novartis Ag Galenic formulations of organic compounds
SI1828167T1 (sl) * 2004-06-04 2014-12-31 Debiopharm International Sa Forum "Apres-Demain" Akrilamidni derivati kot anitibiotična sredstva
US20060247255A1 (en) * 2005-05-02 2006-11-02 Patel Satishkumar A Method for preparing a stable gatifloxacin composition
CA2617230A1 (en) * 2005-08-02 2007-02-08 Baxter International Inc. Medical products and parenteral formulations
WO2007067416A2 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
EP2054422B1 (en) 2006-07-20 2017-06-14 Debiopharm International SA Acrylamide derivatives as fab i inhibitors
CN100415212C (zh) * 2006-07-21 2008-09-03 哈药集团制药总厂 一种含乳酸卡德沙星的口服制剂
CA2563690C (en) * 2006-10-12 2014-10-07 Pharmascience Inc. Pharmaceutical compositions comprising intra- and extra- granular fractions
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
MX356695B (es) 2012-06-19 2018-06-11 Debiopharm Int Sa Profarmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)me til)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il) acrilamida.
KR20180114177A (ko) 2016-02-26 2018-10-17 데비오팜 인터네셔날 에스 에이 당뇨병성 족부 감염의 치료제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた8‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
EP0522128B1 (en) * 1991-01-30 1996-01-17 The Wellcome Foundation Limited Water-dispersible tablets
GB9109862D0 (en) * 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
US5436253A (en) * 1993-09-08 1995-07-25 Daiichi Pharmaceutical Co., Ltd. Pyridonecarboxylic acid derivatives and mycotic infections
US5858411A (en) * 1994-12-19 1999-01-12 Daiichi Pharmaceutical Co., Ltd. Sustained-release granular preparations and production process thereof
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US5837292A (en) * 1996-07-03 1998-11-17 Yamanouchi Europe B.V. Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug

Also Published As

Publication number Publication date
MY118569A (en) 2004-12-31
IL139512A0 (en) 2001-11-25
US6291462B1 (en) 2001-09-18
PT1077703E (pt) 2003-08-29
NO20005385L (no) 2000-10-26
PL343936A1 (en) 2001-09-10
NO20005385D0 (no) 2000-10-26
ATE235242T1 (de) 2003-04-15
PE20000480A1 (es) 2000-05-20
ES2195573T3 (es) 2003-12-01
EP1077703A1 (de) 2001-02-28
JP2002514600A (ja) 2002-05-21
KR20010043408A (ko) 2001-05-25
KR100587210B1 (ko) 2006-06-08
HUP0101597A3 (en) 2003-01-28
BR9910350A (pt) 2001-09-25
NZ507968A (en) 2002-12-20
UA60364C2 (uk) 2003-10-15
HUP0101597A2 (hu) 2001-11-28
SK16772000A3 (sk) 2001-05-10
WO1999058129A1 (de) 1999-11-18
CN1198615C (zh) 2005-04-27
AU4035299A (en) 1999-11-29
CN1300216A (zh) 2001-06-20
DE19820801A1 (de) 1999-11-25
AR019279A1 (es) 2002-02-13
EP1077703B1 (de) 2003-03-26
AU753482B2 (en) 2002-10-17
CO5050341A1 (es) 2001-06-27
CA2325636A1 (en) 1999-11-18
DE59904737D1 (de) 2003-04-30
RU2226394C2 (ru) 2004-04-10
ZA200006440B (en) 2002-02-08
DK1077703T3 (da) 2003-06-23

Similar Documents

Publication Publication Date Title
HUP0101597A3 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
HRPK20040323B3 (en) Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient
AU2002346973A1 (en) Oral Dosage Form for Propiverine or its Pharmaceutically Acceptable Salts with an Extended Release of the Active Ingredient
HUP0900587A3 (en) Stable salts of 3,3-diphenylpropylamines and preparation thereof
IL137445A0 (en) Pharmaceutically active compounds and methods of use thereof
AU3076700A (en) 2h-phthalazin-1-one derivatives and drugs comprising these derivatives as the active ingredient
HUP0101461A3 (en) Novel pyridazine derivatives and drugs containing the same as the active ingredient
EE200100259A (et) Moksifloksatsiini farmatseutiline preparaat
AU7962200A (en) Novel indole derivatives and drugs containing the same as the active ingredient
HK1036757A1 (en) Sustained release oral preparations of fasudil hydrochloride
AU782631C (en) Novel heterocyclic compounds and salts thereof and medicinal use of the same
EP1115396A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS, AND METHODS OF USE THEREOF
HUP0102369A3 (en) Amino acid derivatives and drugs containing the same as the active ingredient
EP1154997A4 (en) PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
EG24397A (en) Salts of keto acids and amine derivatives and their use for the preparation of medicaments
AU1650401A (en) Oxadiazole derivatives and drugs containing these derivatives as the active ingredient
AU2001277738A1 (en) Piperidine derivatives and drugs containing these derivatives as the active ingredient
HUP0201667A3 (en) Oral form of administration
HUP0104238A2 (en) Benzoxazole derivatives and drugs containing the same as the active ingredient and their use
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
AUPP672198A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
IL150403A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
AUPQ462299A0 (en) Pyrazolopyridine compound and pharmaceutical use thereof
SI1077703T1 (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates
IL150402A0 (en) NOVEL PROCESS FOR THE PREPARATION OF α-(2-4-DISULFOPHENYL)-N-TERT-BUTYLNITRONE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF

Legal Events

Date Code Title Description
PF Patent in force
AS Change of ownership

Owner name: KYORIN PHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER(S): GRUNENTHAL GMBH

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20110429